Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22354571 | 0.93 | USP2 (0.62) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL12761114 | 0.87 | USP2 (0.59) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL15025122 | 0.87 | USP2 (0.55) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL21301880 | 0.85 | USP2 (0.53) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL14076168 | 0.85 | USP2 (0.62) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL12056425 | 0.85 | USP2 (0.67) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL14116865 | 0.85 | USP2 (0.67) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL8577317 | 0.83 | USP2 (0.64) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL709506 | 0.81 | USP2 (1.00) | USP2TSHRL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL23158348 | 0.81 | USP2 (0.67) | USP2TSHRL3MBTL1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHEAL W (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHEAL W (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHEAL W (DE) | 2023-04-27 | — | — | US | disclosed |
| US-11420995-B2 | Anti-infective and anti-inflammatory compounds | SYNOVO GMBH (DE) | 2022-08-23 | — | — | US | disclosed |
| WO-2021195126-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHAEL W (DE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021195126-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHAEL W (DE) | 2021-09-30 | — | — | WO | disclosed |
| US-20200262857-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2020-08-20 | — | — | US | disclosed |
| US-20200262857-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2020-08-20 | — | — | US | disclosed |
| WO-2018161039-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | CTSA, GAA, SLC7A5 | USP2 571/4885TSHR 4510/4885L3MBTL1 1536/4885 |
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | CTSA, ALOX15, ALOX5 | USP2 928/4885TSHR 4450/4885L3MBTL1 1562/4885 |
| US-11420995-B2 | Anti-infective and anti-inflammatory compounds | CTSA, ALOX15, ALOX12 | USP2 1409/4885TSHR 4335/4885L3MBTL1 1261/4885 |
| US-20200262857-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | CTSA, ALOX15, ALOX5 | USP2 928/4885TSHR 4450/4885L3MBTL1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.